These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10599370)

  • 1. Toxicity profile of methotrexate in rheumatoid arthritis. A preliminary survey.
    Coleiro B; Mallia C
    Adv Exp Med Biol; 1999; 455():359-65. PubMed ID: 10599370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis.
    Pincus T
    Clin Exp Rheumatol; 1998; 16(6):667-8. PubMed ID: 9844757
    [No Abstract]   [Full Text] [Related]  

  • 3. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
    Ortiz Z; Shea B; Suarez Almazor M; Moher D; Wells G; Tugwell P
    Cochrane Database Syst Rev; 2000; (2):CD000951. PubMed ID: 10796393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of methotrexate in older patients. A risk-benefit assessment.
    Tett SE; Triggs EJ
    Drugs Aging; 1996 Dec; 9(6):458-71. PubMed ID: 8972245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of low dose methotrexate in rheumatoid arthritis patients.
    Gilani ST; Khan DA; Khan FA; Ahmed M
    J Coll Physicians Surg Pak; 2012 Feb; 22(2):101-4. PubMed ID: 22313647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
    Nash P; Nicholls D
    Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics related to methotrexate-induced pancytopenia.
    Ohosone Y; Okano Y; Kameda H; Hama N; Mimori T; Akizuki M; Ikeda Y
    Clin Rheumatol; 1997 May; 16(3):321-3. PubMed ID: 9184276
    [No Abstract]   [Full Text] [Related]  

  • 8. [Toxicity of low-dose methotrexate in rheumatoid arthritis--clinical characteristics in patients with MTX-induced pancytopenia and interstitial pneumonitis].
    Ohosone Y; Okano Y; Kameda H; Hama N; Matsumura M; Nojima T; Nakamura K; Kuwana M; Ogasawara T; Hirakata M; Yoshida T; Mimori T; Akizuki M; Ikeda Y
    Ryumachi; 1997 Feb; 37(1):16-23. PubMed ID: 9128419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
    Shea B; Swinden MV; Ghogomu ET; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
    J Rheumatol; 2014 Jun; 41(6):1049-60. PubMed ID: 24737913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?
    Cansu DÜ; Teke HÜ; Bodakçi E; Korkmaz C
    Clin Rheumatol; 2018 Dec; 37(12):3419-3425. PubMed ID: 30056523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methotrexate treatment of rheumatoid arthritis].
    Beyeler C
    Schweiz Med Wochenschr; 1996 Apr; 126(17):703-12. PubMed ID: 8668981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment: severe pancytopenia associated with methotrexate therapy for rheumatoid arthritis.
    Mofredj A; Baraka D; Charoud A
    Ann Pharmacother; 2002; 36(7-8):1295. PubMed ID: 12086573
    [No Abstract]   [Full Text] [Related]  

  • 13. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serious adverse effects of methotrexate therapy in patients with rheumatic arthritis].
    Purokivi M; Myllykangas-Luosujärvi R; Jantunen E
    Duodecim; 1998; 114(21):2187-90. PubMed ID: 11757107
    [No Abstract]   [Full Text] [Related]  

  • 15. Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis.
    Castaneda O; Nair MG
    J Rheumatol; 2006 May; 33(5):862-4. PubMed ID: 16652417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review.
    Wang W; Zhou H; Liu L
    Eur J Med Chem; 2018 Oct; 158():502-516. PubMed ID: 30243154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Ureña et al.
    Berthelot JM; Maugars Y; Prost A
    Arthritis Rheum; 1997 Jan; 40(1):193-4; author reply 195-6. PubMed ID: 9008619
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.
    Prey S; Paul C
    Br J Dermatol; 2009 Mar; 160(3):622-8. PubMed ID: 18945303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An audit of methotrexate and folic acid for rheumatoid arthritis. Experience from a teaching centre.
    Jobanputra P; Hunter M; Clark D; Lambert CM; Hurst NP
    Br J Rheumatol; 1995 Oct; 34(10):971-5. PubMed ID: 7582706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs].
    Jiang L; Zhao N; Ni L
    Zhonghua Liu Xing Bing Xue Za Zhi; 2002 Jun; 23(3):213-7. PubMed ID: 12411093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.